Opus Point Partners Management as of Sept. 30, 2017
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 60 positions in its portfolio as reported in the September 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 7.7 | $8.6M | 135k | 63.74 | |
| Proshares Tr pshs ult nasb (BIB) | 7.2 | $8.0M | 131k | 61.25 | |
| Alexion Pharmaceuticals | 5.8 | $6.5M | 46k | 140.30 | |
| SPDR S&P Biotech (XBI) | 5.0 | $5.6M | 65k | 86.57 | |
| Alnylam Pharmaceuticals (ALNY) | 5.0 | $5.6M | 48k | 117.49 | |
| Merck & Co (MRK) | 4.8 | $5.4M | 84k | 64.03 | |
| iShares NASDAQ Biotechnology Index (IBB) | 3.7 | $4.2M | 13k | 333.60 | |
| AstraZeneca (AZN) | 3.6 | $4.1M | 120k | 33.88 | |
| Pfizer (PFE) | 3.6 | $4.0M | 112k | 35.70 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.5 | $2.8M | 18k | 152.02 | |
| Nektar Therapeutics (NKTR) | 2.2 | $2.5M | 104k | 24.00 | |
| Alkermes (ALKS) | 2.2 | $2.5M | 48k | 50.85 | |
| GlaxoSmithKline | 2.2 | $2.4M | 60k | 40.60 | |
| Celgene Corporation | 2.1 | $2.4M | 16k | 145.82 | |
| Incyte Corporation (INCY) | 2.1 | $2.4M | 20k | 116.74 | |
| Mettler-Toledo International (MTD) | 2.0 | $2.2M | 3.6k | 626.04 | |
| Seattle Genetics | 2.0 | $2.2M | 41k | 54.41 | |
| Illumina (ILMN) | 2.0 | $2.2M | 11k | 199.20 | |
| Ionis Pharmaceuticals (IONS) | 2.0 | $2.2M | 44k | 50.70 | |
| Agios Pharmaceuticals (AGIO) | 2.0 | $2.2M | 33k | 66.75 | |
| Amgen (AMGN) | 1.9 | $2.1M | 11k | 186.48 | |
| Ignyta | 1.9 | $2.1M | 171k | 12.35 | |
| Biogen Idec (BIIB) | 1.9 | $2.1M | 6.7k | 313.14 | |
| Regeneron Pharmaceuticals (REGN) | 1.8 | $2.0M | 4.6k | 447.05 | |
| Qiagen Nv | 1.8 | $2.0M | 64k | 31.50 | |
| BioMarin Pharmaceutical (BMRN) | 1.7 | $1.9M | 20k | 93.09 | |
| Direxion Shs Etf Tr sp biotch bl | 1.2 | $1.4M | 16k | 85.49 | |
| Gilead Sciences (GILD) | 1.2 | $1.3M | 17k | 81.09 | |
| Eli Lilly & Co. (LLY) | 1.1 | $1.3M | 15k | 85.53 | |
| Loxo Oncology | 1.1 | $1.3M | 14k | 92.10 | |
| Clovis Oncology | 1.1 | $1.2M | 15k | 82.40 | |
| Karyopharm Therapeutics (KPTI) | 1.0 | $1.1M | 100k | 10.98 | |
| Paratek Pharmaceuticals | 0.9 | $1.0M | 40k | 25.10 | |
| Pacira Pharmaceuticals (PCRX) | 0.8 | $939k | 25k | 37.56 | |
| Axsome Therapeutics (AXSM) | 0.7 | $741k | 134k | 5.55 | |
| Juno Therapeutics | 0.6 | $660k | 15k | 44.84 | |
| Tesaro | 0.6 | $646k | 5.0k | 129.20 | |
| Ultragenyx Pharmaceutical (RARE) | 0.6 | $634k | 12k | 53.28 | |
| Adamas Pharmaceuticals | 0.6 | $635k | 30k | 21.17 | |
| Bioverativ Inc Com equity | 0.6 | $631k | 11k | 57.07 | |
| Neurocrine Biosciences (NBIX) | 0.5 | $591k | 9.6k | 61.28 | |
| ACADIA Pharmaceuticals (ACAD) | 0.5 | $589k | 16k | 37.66 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.5 | $543k | 25k | 21.89 | |
| Charles River Laboratories (CRL) | 0.5 | $535k | 5.0k | 107.97 | |
| Medicines Company | 0.5 | $519k | 14k | 37.07 | |
| Quintiles Transnatio Hldgs I | 0.5 | $515k | 5.4k | 95.14 | |
| Bio-techne Corporation (TECH) | 0.5 | $516k | 4.3k | 120.90 | |
| Checkpoint Therapeutics | 0.5 | $507k | 113k | 4.50 | |
| United Therapeutics Corporation (UTHR) | 0.4 | $481k | 4.1k | 117.09 | |
| Intrexon | 0.4 | $455k | 24k | 19.02 | |
| Akebia Therapeutics (AKBA) | 0.4 | $413k | 21k | 19.66 | |
| New Senior Inv Grp | 0.3 | $383k | 42k | 9.15 | |
| Intercept Pharmaceuticals In | 0.2 | $260k | 4.5k | 58.02 | |
| Heron Therapeutics (HRTX) | 0.2 | $256k | 16k | 16.13 | |
| Avexis | 0.2 | $242k | 2.5k | 96.80 | |
| Recro Pharma (SCTL) | 0.2 | $227k | 25k | 9.00 | |
| Ligand Pharmaceuticals In (LGND) | 0.2 | $207k | 1.5k | 136.27 | |
| Contrafect | 0.1 | $167k | 150k | 1.11 | |
| Progenics Pharmaceuticals | 0.1 | $160k | 22k | 7.35 | |
| Scynexis | 0.1 | $161k | 67k | 2.42 |
